Elizabeth DeVilbiss

Dr. Elizabeth DeVilbiss

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAlaina M. Bever
Alaina M. Bever
SMSunni L. Mumford
Sunni L. Mumford
ESEnrique F. Schisterman
Enrique F. Schisterman
LSLindsey Sjaarda
Lindsey Sjaarda
NPNeil J. Perkins
Neil J. Perkins
KGKatherine L. Grantz
Katherine L. Grantz
In 575 women with 1–2 prior pregnancy losses; total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were evaluated preconception and throughout pregnancy to evaluate whether previously observed associations between third trimester maternal lipid profile and birthweight outcomes are driven by preconception lipids or lipid changes during pregnancy. Lipid trajectories were compared by pre-pregnancy body mass index (BMI) <25 or ≥25 kg/m2; logistic regression models evaluated preconception lipid concentration and change from preconception to 28 weeks with adjusted odds of large- or small-for-gestational age (LGA or SGA) neonate by BMI group. Preconception lipid concentrations and gestational lipid trajectories varied by BMI group (P < 0.001). Preconception lipids were not associated with LGA or SGA in either group. A 10 mg/dL increase in HDL-C change from preconception to 28 weeks was associated with decreased odds of LGA (odds ratio (OR) = 0.63, 95% confidence interval (CI): 0.46, 0.86) and 10 mg/dL increase in TG change associated with increased odds of LGA (OR = 1.05, 95% CI: 1.01, 1.1) overall. For ≥25 BMI only, 10 mg/dL increase in HDL-C change was associated with decreased SGA odds (OR = 0.35, 95% CI: 0.19, 0.64). Gestational lipid trajectories differed by BMI group and were differentially associated with birthweight outcomes, with HDL-C more strongly associated with healthy birthweight in women with BMI ≥25.

12 November 2019 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ESEnrique F Schisterman
Enrique F Schisterman
TCTraci Clemons
Traci Clemons
MPMatthew Peterson
Matthew Peterson
EJErica Johnstone
Erica Johnstone
AHAhmad O Hammoud
Ahmad O Hammoud
SMSunni L Mumford
Sunni L Mumford
The Folic Acid and Zinc Supplementation Trial (FAZST) was a multicenter, double-blind, block-randomized, placebo-controlled trial to determine whether folic acid and zinc supplementation in men improves semen quality and increases livebirth rate among couples seeking infertility treatment (2013–2017). Eligible men were aged 18 years or older with female partners aged 18–45 years, seeking infertility treatment. Men were randomized (1:1) to 5 mg folic acid and 30 mg elemental zinc daily or matching placebo for 6 months. Randomization was stratified by site and intended infertility treatment (in vitro fertilization (IVF), non-IVF/study site, and non-IVF/outside clinic). Follow-up of men continued for 6 months, and female partners were passively followed for a minimum of 9 months. Women who conceived were followed throughout pregnancy. Overall, 2,370 men were randomized during 2013–2017 (1,185 folic acid and zinc, 1,185 placebo); they had a mean age of 33 years and body mass index (weight (kg)/height (m)2) of 29.8. Most participants were white (82%), well educated (83% with some college), and employed (72%). Participant characteristics were balanced across intervention arms. Study visits were completed by 89%, 77%, and 75% of men at months 2, 4, and 6, respectively. Here we describe the study design, recruitment, data collection, lessons learned, and baseline participant characteristics.

1 October 2022 in Fertility and Sterility
Verified
Journal Article
Closed access
EDElizabeth DeVilbiss
Elizabeth DeVilbiss
LSLindsey A. Sjaarda
Lindsey A. Sjaarda
CPC. Matthew Peterson
C. Matthew Peterson
JHJames M. Hotaling
James M. Hotaling
JMJames L. Mills
James L. Mills
SMSunni L. Mumford
Sunni L. Mumford

14 January 2022 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
APAlexandra C Purdue-Smithe
Alexandra C Purdue-Smithe
KKKeewan Kim
Keewan Kim
KSKaren C Schliep
Karen C Schliep
EDElizabeth DeVilbiss
Elizabeth DeVilbiss
SHStefanie N Hinkle
Stefanie N Hinkle
SMSunni Mumford
Sunni Mumford
Caffeine is the most frequently used psychoactive substance in the United States and >90% of reproductive-age women report some amount of intake daily. Despite biological plausibility, previous studies on caffeine and fecundability report conflicting results. Importantly, prior studies measured caffeine exposure exclusively by self-report, which is subject to measurement error and does not account for factors that influence caffeine metabolism. Our objective was to examine associations between preconception serum caffeine metabolites, caffeinated beverage intake, and fecundability. Participants included 1228 women aged 18–40 y with a history of 1–2 pregnancy losses in the EAGeR (Effects of Aspirin in Gestation and Reproduction) trial. We prospectively evaluated associations of preconception caffeine metabolites (i.e., caffeine, paraxanthine, and theobromine) measured from 1191 serum samples untimed to a specific time of day, self-reported usual caffeinated beverage intakes at baseline, and time-varying cycle-average caffeinated beverage intake, with fecundability. Using Cox proportional hazards models, we estimated fecundability odds ratios (FORs) and 95% CIs according to each metabolite. Follow-up was complete for 89% (n = 1088) of participants. At baseline, 85%, 73%, and 91% of women had detectable serum caffeine, paraxanthine, and theobromine, respectively. A total of 797 women became pregnant during ≤6 cycles of preconception follow-up. After adjusting for potential confounders, neither serum caffeine [tertile (T)3 compared with T1 FOR: 0.87; 95% CI: 0.71, 1.08], paraxanthine (T3 compared with T1 FOR: 0.92; 95% CI: 0.75, 1.14), nor theobromine (T3 compared with T1 FOR: 1.15; 95% CI: 0.95, 1.40) were associated with fecundability. Baseline intake of total caffeinated beverages was not associated with fecundability (>3 compared with 0 servings/d adjusted FOR: 0.99; 95% CI: 0.74, 1.34), nor was caffeinated coffee (>2 compared with 0 servings/d adjusted FOR: 0.93; 95% CI: 0.45, 1.92) or caffeinated soda (>2 servings/d adjusted FOR: 0.92; 95% CI: 0.71, 1.20). Our findings are reassuring that caffeine exposure from usual low to moderate caffeinated beverage intake likely does not influence fecundability. This trial was registered at clinicaltrials.gov as NCT00467363.

21 August 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
SLShan Xuan Lim
Shan Xuan Lim
SWSiona Wadhawan
Siona Wadhawan
EDElizabeth DeVilbiss
Elizabeth DeVilbiss
PCPriscilla Kay Clayton
Priscilla Kay Clayton
KWKathryn A. Wagner
Kathryn A. Wagner
JGJagteshwar Grewal
Jagteshwar Grewal
Background/Objectives: Suboptimal gestational weight gain (GWG) has been linked to increased risks of adverse maternal outcomes. Evidence linking diet in pregnancy to GWG remains limited. We assessed relationships between adherence to five dietary patterns (Planetary Health Diet [PHD], Dietary Approaches to Stop Hypertension [DASH], Alternate Mediterranean Diet [AMED], Healthy Eating Index [HEI], and Alternate Healthy Eating Index [AHEI]) and 2009 Institute of Medicine GWG categories. Methods: Women expecting singleton pregnancies participated in the NICHD Fetal Growth Studies and completed a food-frequency questionnaire (FFQ) at 8 to 13 weeks of gestation that captured their baseline diet. Adherence to each dietary pattern was calculated, with higher scores indicating greater adherence. Women were categorized into low, moderate or high adherence to each dietary pattern. Using multinomial logistic regression, we estimated adjusted odds ratios and 95% confidence intervals [OR (95% CIs)] of inadequate or excessive GWG (reference category: adequate), for high vs. low adherence to each dietary pattern. Results: In the full cohort, women with high vs. low adherence to DASH, AMED, HEI, or AHEI (but not PHD) had a 13% to 31% lowered odds of inadequate total GWG [ranging from 0.87 (0.58, 1.31) for AMED to 0.69 (0.48, 0.99) for DASH]. High adherence to DASH or HEI was associated with lower odds of inadequate first-trimester GWG, after correcting for multiple testing [DASH: 0.36 (0.22, 0.61), HEI: 0.49 (0.30, 0.79)]. No significant association was observed between any of the dietary patterns and excessive total and trimester-specific GWG. Conclusions: Greater adherence to several dietary patterns was associated with lowered odds of inadequate GWG. Future studies could characterize these diets objectively by identifying metabolite signatures and examining their associations with GWG.

1 September 2020 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
ESEnrique F. Schisterman
Enrique F. Schisterman
EDElizabeth DeVilbiss
Elizabeth DeVilbiss
NPNeil J. Perkins
Neil J. Perkins
Loss to follow-up occurs in randomized controlled trials. Missing data methods, including multiple imputation (MI), can be used but often rely upon untestable assumptions. Sensitivity analysis can quantify violations of these assumptions. Since an adequate sensitivity analysis requires evaluation of multiple scenarios, presenting this information in an easily interpretable manner is challenging. We propose to graphically represent a thorough sensitivity analysis displaying all possible outcomes for loss to follow-up in randomized controlled trial data relating a completely observed binary exposure to a binary outcome. We describe plausible results under different missingness mechanisms using data from the EAGeR Trial (n = 1228) on low-dose aspirin versus placebo on pregnancy and live birth, in which 140 participants had early withdrawal. For the effect of aspirin on live birth, sensitivity analysis risk ratios (RR) for all potential outcome scenarios ranged from 0.88 to 1.34, applicable to any possible missingness mechanism. MI produced RR = 1.10; 95% confidence interval: (0.98, 1.22). RRs from individual imputations ranged from 1.04 to 1.16, the range of results that could have been observed if data were missing at random. Under this mechanism, the conclusions about the efficacy of low-dose aspirin could have been sensitive to the missing outcome data. Rather than limiting sensitivity analysis for loss to follow-up to a few scenarios that can be presented tabularly, results of a complete sensitivity analysis can be presented in a single plot, which should be implemented in all studies with missing outcome data to convey certainty or uncertainty, confidence or caution.